A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

This study is testing a drug called XNW5004 in people with peripheral T-cell lymphoma (PTCL) — a type of aggressive blood cancer involving T-cells — whose cancer has come back or stopped responding to previous treatment. XNW5004 belongs to a class of drugs called HDAC inhibitors, which work by altering how cancer cells grow and divide. **You may be eligible if...** - You are between 18 and 70 years old - You have peripheral T-cell lymphoma confirmed by pathology testing - Your cancer has relapsed or is refractory (not responding) after at least one prior treatment - You have not previously received an HDAC inhibitor drug - You have at least one measurable tumor - You are willing to provide tumor tissue samples **You may NOT be eligible if...** - You have previously been treated with an HDAC inhibitor - You have certain subtypes requiring specific prior treatments that you have not received (e.g., NK/T-cell lymphoma without prior asparaginase-based therapy) - Your general health or organ function does not meet required levels Talk to your doctor to see if this trial is right for you.